Eli Lilly and Company vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored

Cost Efficiency in Pharma: Eli Lilly vs. BioCryst

__timestampBioCryst Pharmaceuticals, Inc.Eli Lilly and Company
Wednesday, January 1, 20141220004932500000
Thursday, January 1, 201518960005037200000
Friday, January 1, 201626990005654900000
Sunday, January 1, 201717020006070200000
Monday, January 1, 20184710004681700000
Tuesday, January 1, 201941010004721200000
Wednesday, January 1, 202016760005483300000
Friday, January 1, 202172640007312800000
Saturday, January 1, 202265940006629800000
Sunday, January 1, 202346610007082200000
Monday, January 1, 20248418299999
Loading chart...

Unleashing the power of data

Exploring Cost Efficiency in Pharmaceuticals: Eli Lilly vs. BioCryst

In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for two industry players: Eli Lilly and Company and BioCryst Pharmaceuticals, Inc., from 2014 to 2023.

Eli Lilly, a giant in the sector, consistently reported a cost of revenue in the billions, peaking at approximately $7.3 billion in 2021. In contrast, BioCryst, a smaller entity, showed a more modest cost of revenue, reaching its highest at around $7.3 million in the same year.

Over the decade, Eli Lilly's cost of revenue increased by about 43%, while BioCryst's fluctuated significantly, highlighting the challenges smaller companies face in maintaining cost efficiency. This comparison underscores the scale and operational differences between large and small pharmaceutical companies, offering insights into their financial strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025